[October 21, 2014]

Research and Markets: Roche/Genentech's Perjeta (HER2-Positive Breast Cancer Treatment) - Forecast and Market Analysis to 2023

Research and Markets (http://www.researchandmarkets.com/research/b5pjfn/perjeta) has announced the addition of the "Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering.

Perjeta (pertuzumab) is the second biologic to launch in Roche/Genentech's HER2-targeted therapy portfolio, and was approved by the FDA in 2012, and by the EMA (News - Alert) and the Japanese Ministry of Health, Labour and Welfare (MHLW) in 2013. Like Herceptin, Perjeta is a monoclonal antibody (mAb) that targets HER2; however, Perjeta's mechanism of action is slightly different: whereas Herceptin blocks the binding of ligands to HER2, Perjeta binds to the extracellular dimeriztion domain of HER2, inhibiting ligand-dependent dimerization of the HER receptors.

Scope

• Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Perjeta including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Perjeta for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

• Etiology and Pathophysiology
• Basic Breast Anatomy
• Breast Cancer Staging
• Prognosis (News - Alert)
• Quality of Life
• Symptoms

4 Disease Management

• Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
• Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
• Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)

5 Competitive Assessment

6 Perjeta (pertuzumab)

• Efficacy
• Safety
• SWOT Analysis
• Forecast

7 Appendix

For more information visit http://www.researchandmarkets.com/research/b5pjfn/perjeta

[ Back To TMCnet.com's Homepage ]